Reversing the suppression of T-cells: the role of monoclonal antibodies Source: International Congress 2015 – Stop immune tolerance in lung cancer! Year: 2015
Is Fezakinumab, an anti-IL22 antibody, a putative novel therapy for a subset of severe asthma? Source: International Congress 2019 – Novel molecular pathways in lung cancer and COPD Year: 2019
Specific monoclonal antibody to detect the C-terminal peptide of alpha1-antitrypsin: clinical importance Source: International Congress 2019 – Chronic cough, a1-antitrypsin deficiency and other conditions Year: 2019
The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma Source: Eur Respir J 2001; 18: 45-52 Year: 2001
A patient-derived lung-on-chip model to evaluate on-target/off-tumour toxicity of the therapeutic FOLR1-targeting T-Cell Bispecific antibody Source: Virtual Congress 2021 – In vitro modelling of lung disease: reach out to the next dimension Year: 2021
A multiple ascending subcutaneous (SC) dose study of MEDI-563, a humanized anti-IL-5Rα monoclonal antibody, in adult asthmatics Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010
Safety profile and clinical activity of multiple subcutaneous (SC) doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in subjects with asthma Source: Annual Congress 2010 - Novel anti-inflammatory agents for airway disease Year: 2010
Differences in the response to treatment with monoclonal antibodies according to age Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020
Anti-interleukin-13 antibody therapy for asthma: one step closer Source: Eur Respir J 2013; 41: 255-256 Year: 2013
Efficacy and safety of anti-PD-L1 antibody in NSCLC patients who previously treated with anti PD-1 antibodies Source: International Congress 2019 – Treatment of lung cancer Year: 2019
Phase 1 study of a novel, prolonged-action anti-IL-5 monoclonal antibody in asthma Source: Virtual Congress 2021 – Clinical trials in airway diseases: novel treatments and new evidence Year: 2021
PP129 – Safety evaluation of cancer immunotherapy in a lung-on-chip model: the therapeutic FOLR1 targeting T Cell Bispecific antibody Source: ERS Lung Science Conference 2021 Year: 2021
A novel anti-IgE immunotherapeutic, RP01, induces anti-IgE antibodies in human subjects; data from a phase I study Source: Eur Respir J 2007; 30: Suppl. 51, 622s Year: 2007
Impact of age on the efficacy of anti-IL-5 monoclonal antibodies in severe asthmatics Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019
Effects of anti-M1 prime monoclonal antibody, MEMP1972A following allergen challenge in patients with mild asthma Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012
Massive monoclonal expansion of CD4 T-cells specific for a Mycobacterium tuberculosis ESAT-6 peptide Source: Eur Respir J 2012; 40: 152-160 Year: 2012
Long-term treatment with monoclonal antibodies anti-IgE in severe asthma: Follow-up of ten patients Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011
Change of lung function in severe eosinophilic asthma undergoing treatment with anti-interleukin-5 monoclonal antibody Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018
Determining early response to anti-IL5/IL5R monoclonal antibodies in severe eosinophilic asthma Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020